Trial Profile
A Phase 1 Open-Label, Dose Escalation Study to Determine the Absolute Bioavailability of a Single Oral Dose Administration of Decitabine in Patients With Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2019
Price :
$35
*
At a glance
- Drugs Decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 11 Dec 2018 A population pharmacokinetic model was developed by pooling decitabine concentration-time data from 5 adult (AML and MDS) and 2 pediatric (AML) studies (DACO-018, DACO-017, DACO-020, DACO-016, E7373-A001-101, E7373-G000-202 and DACOGENAML2004 trial); results published in the Journal of Clinical Pharmacology
- 22 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.